K Späthe

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

Barbara Schmalfeldt, Dieter Prechtel, Kathrin Härting et al. · PubMed · 2001 · 336 citations

Medicine, Gynecology, Oncology +16

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

Walther Kuhn, Stefan Rutke, K Späthe et al. · Cancer · 2001 · 211 citations

Medicine, Oncology, Surgery +17

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

W. Kühn, Barbara Schmalfeldt, Ute Reuning et al. · British Journal of Cancer · 1999 · 130 citations · Full text

Medicine, Gynecology, Oncology +16

Expression of Latent Matrix Metalloproteinase 9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer

Ernst Lengyel, Barbara Schmalfeldt, Elisabeth Konik et al. · Gynecologic Oncology · 2001 · 115 citations

Medicine, Cancer Biology, Oncology +14

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

Felix Hilpert, A. Stähle, O. Tomé et al. · Supportive Care in Cancer · 2005 · 70 citations

Medicine, Oncology, Pharmacology +13